Alexandra Papaioannou

Prof. Alexandra Papaioannou


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 January 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
VNVASILEIA NYKTARI
VASILEIA NYKTARI
GSGeorgios Stefanakis
Georgios Stefanakis
GPGeorgios Papastratigakis
Georgios Papastratigakis
HDHelen Diamantaki
Helen Diamantaki
EKEmmanouela koutoulaki
Emmanouela koutoulaki
APAlexandra Papaioannou
Alexandra Papaioannou
Background/Objectives: To assess the feasibility and effectiveness of a perioperative opioid-sparing anesthesia-analgesia (OSA-A) technique without regional nerve blocks compared to standard opi-oid-based technique (OBA-A) in open thoracotomies. Methods: This retrospective, propensi-ty-matched, case-control study was conducted at a university hospital from January 2017 to Feb-ruary 2021, including adult patients undergoing open thoracotomy for lung or pleura pathology. Sixty patients in the OSA-A group were matched with 40 in the OBA-A group. Outcomes included postoperative pain scores on days 0, 1, and 2; 24-hour postoperative morphine consumption; PACU and hospital length of stay; time to bowel movement; and rates of nausea and vomiting. Results: Of 120 eligible patients, 100 had complete records (60 OSA-A, 40 OBA-A). Demographics were similar, but ASA status scores were higher in the OBA-A group. The OSA-A group reported significantly lower pain levels at rest, during cough, and on movement on the first two postoperative days, shorter PACU stay, and required fewer opioids. They also had better gastrointestinal motility (p<0.0001) and lower rates of nausea and vomiting on postoperative days 1 and 2. A follow-up study with 68 patients (46 OSA-A, 22 OBA-A) assessing chronic pain prevalence found no signif-icant differences between the groups. Conclusions: OSA-A without regional nerve blocks for open thoracotomies is feasible and safe, improving postoperative pain management, reducing opioid consumption, shortening PACU stay, and enhancing early gastrointestinal recovery compared to OBA-A.

Verified
Journal Article
Open access
PDF file
VNVASILEIA NYKTARI
VASILEIA NYKTARI
GSGeorgios Stefanakis
Georgios Stefanakis
GPGeorgios Papastratigakis
Georgios Papastratigakis
EDEleni Diamantaki
Eleni Diamantaki
EKEmmanouela koutoulaki
Emmanouela koutoulaki
APAlexandra Papaioannou
Alexandra Papaioannou
Background/Objectives: To assess the feasibility and effectiveness of a perioperative opioid-sparing anesthesia-analgesia (OSA-A) technique without regional nerve blocks compared to standard opioid-based technique (OBA-A) in open thoracotomies. Methods: This retrospective, matched cohort study was conducted at a university hospital from September 2019 to February 2021, including adult patients undergoing open thoracotomy for lung or pleura pathology. Sixty patients in the OSA-A group were matched with 40 in the OBA-A group. Outcomes included postoperative pain scores on days 0, 1, and 2; 24-h postoperative morphine consumption; PACU and hospital length of stay; time to bowel movement; and rates of nausea and vomiting. Results: Of 125 eligible patients, 100 had complete records (60 OSA-A, 40 OBA-A). Demographics were similar, but ASA status scores were higher in the OBA-A group. The OSA-A group reported significantly lower pain levels at rest, during cough, and on movement on the first two postoperative days, shorter PACU stay, and required fewer opioids. They also had better gastrointestinal motility (p < 0.0001) and lower rates of nausea and vomiting on postoperative days 1 and 2. A follow-up study with 68 patients (46 OSA-A, 22 OBA-A) assessing chronic pain prevalence found no significant differences between the groups. Conclusions: OSA-A without regional nerve blocks for open thoracotomies is feasible and safe, improving postoperative pain management, reducing opioid consumption, shortening PACU stay, and enhancing early gastrointestinal recovery compared to OBA-A.

7 August 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
CHRISTINA MAVROGIANNOPOULOU
CHRISTINA MAVROGIANNOPOULOU
GPGeorgios Papastratigakis
Georgios Papastratigakis
EKEmmanouela koutoulaki
Emmanouela koutoulaki
PVPanagiotis Vardakis
Panagiotis Vardakis
GSGeorgios Stefanakis
Georgios Stefanakis
VNVASILEIA NYKTARI
VASILEIA NYKTARI
Background/Objectives: Cancer represents a significant health challenge, with high mortality and morbidity rates. Its diagnosis often triggers chronic stress, adversely affecting patient outcomes. Exercise has emerged as complementary therapy, enhancing treatment adherence and mitigating the side effects of chemotherapy. This study examines the effects of mild exercise during chemotherapy on patient anxiety. Methods: This prospective paired cohort study was conducted in the General Oncology Hospital of Kifisia “Agioi Anargyroi” in Athens, Greece. Adult cancer patients undergoing chemotherapy participated, excluding those with cognitive, hearing, or motor impairments, those who experienced side effects, or those who declined consent. Anxiety was measured before and after a 20-minute exercise routine performed during chemotherapy, using the Greek-translated State–Trait Anxiety Inventory (STAI). The exercise regimen included warm-up, full-body stretching, and cool-down exercises. Pre- and post-exercise scores were analyzed using the Wilcoxon signed-rank test. Results: Forty-five patients (20 women, 25 men; mean age 69.02 ± 10.62 years) with various cancer backgrounds participated. Pre-intervention anxiety levels were in the borderline “moderate” range, dropping post-exercise to the “low” range. Mean STAI scores decreased from 37.73 ± 13.33 to 32.00 ± 14.22 (p < 0.0001), with a medium-large effect size (Cohen’s d for paired samples = −0.646). No significant correlation was found between age and anxiety scores. Discussion: This study found a significant short-term reduction in anxiety, suggesting that incorporating mild exercise during chemotherapy may help in alleviating patient stress. The medium-to-large effect size supports the potential for meaningful short-term benefits. Conclusions: Incorporating mild exercise during chemotherapy may help reduce anxiety and psychological burden. These findings underscore the need for more comprehensive research in larger, more diverse populations to better understand the benefits of incorporating mild exercise during chemotherapy.

23 September 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
AKALEXANDRA KOULOUSI
ALEXANDRA KOULOUSI
CMChrysi Mandola
Chrysi Mandola
GPGeorgios Papastratigakis
Georgios Papastratigakis
FCFoteini Chaniotaki
Foteini Chaniotaki
IGIoannis Goniotakis
Ioannis Goniotakis
VNVASILEIA NYKTARI
VASILEIA NYKTARI
Background/Objectives: 3-Hydroxy-3-methylglutaryl-CoA lyase deficiency (HMGCLD) is an extremely rare autosomal recessive metabolic disorder caused by mutations in the HMGCL gene. HMGCLD disrupts ketogenesis and β-oxidation, leading to energy failure during fasting or stress, with clinical episodes characterized by hypoglycemia, hyperammonemia, lactic acidosis, and encephalopathy. Only 211 cases have been reported worldwide, with no prior reports on anesthetic management in these patients. Clinical features: We report a 14.5-year-old girl with known HMGCLD who was admitted with abdominal pain and nausea following a fatty meal. Imaging confirmed acute cholecystitis. Initial conservative management failed due to persistent vomiting and inability to tolerate feeding. Deviation from the metabolic protocol led to lactic acidosis and hypoglycemia, requiring intensive care with bicarbonate, carnitine, and glucose infusion. Once optimized, she underwent emergency laparoscopic cholecystectomy under sevoflurane-based anesthesia. Propofol was avoided given the patient’s compromised lipid metabolism. Intraoperative glucose and acid-base status were closely monitored, with balanced dextrose-based fluids. The patient remained hemodynamically stable throughout and was discharged three days postoperatively. Conclusions: This case highlights the anesthetic challenges of HMGCLD, where system-level miscommunication can trigger severe metabolic decompensation. A review of the literature emphasizes fasting avoidance, continuous glucose supplementation, careful drug and fluid selection, and multidisciplinary coordination. This report provides the first anesthetic roadmap for HMGCLD, underscoring the need for individualized care and meticulous perioperative metabolic control.

7 July 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
CHRISTINA MAVROGIANNOPOULOU
CHRISTINA MAVROGIANNOPOULOU
GPGeorgios Papastratigakis
Georgios Papastratigakis
EKEmmanouela koutoulaki
Emmanouela koutoulaki
PVPanagiotis Vardakis
Panagiotis Vardakis
GSGeorgios Stefanakis
Georgios Stefanakis
VNVASILEIA NYKTARI
VASILEIA NYKTARI
Background/Objectives: Cancer represents a significant health challenge, with high mortality and morbidity rates. Such a diagnosis often triggers chronic stress, adversely affecting patient outcomes. Exercise has emerged as a complementary therapy, enhancing treatment adherence and mitigating the side effects of chemotherapy. This study examines the effects of mild exercise during chemotherapy on patient anxiety levels. Methods: This prospective paired cohort study was conducted at the General Oncology Hospital of Kifisia "Agioi Anargyroi" in Athens, Greece. Adult cancer patients undergoing chemotherapy participated, excluding those with cognitive, hearing, or motor impairments, side effects, or who declined consent. Anxiety was measured before and after a 20-minute exercise routine performed during chemotherapy, using the Greek-translated State-Trait Anxiety Inventory (STAI). The exercise regimen included warm-up, full-body stretching, and cool-down exercises. Pre- and post-exercise scores were analyzed using the Wilcoxon signed-rank test. Results: Forty-five patients (20 women, 25 men; mean age 69.02 ± 10.62 years) with various cancers participated. Pre-intervention anxiety levels were in the borderline "moderate" range, dropping post-exercise to the "low" range. Mean STAI scores decreased from 37.73 ± 13.33 to 32.00 ± 14.22 (p < 0.0001), with a medium-large effect size (Cohen's d for paired samples = -0.646). No significant correlation was found between age and anxiety scores. Conclusions: This study found a significant short-term reduction in anxiety, suggesting that incorporating mild exercise during chemotherapy may help alleviate patient stress. The medium-to-large effect size supports the potential for meaningful short-term benefits. These findings underscore the need for more comprehensive research in larger, more diverse populations to better understand the benefits of incorporating mild exercise into chemotherapy

17 October 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
VNVASILEIA NYKTARI
VASILEIA NYKTARI
GPGeorgios Papastratigakis
Georgios Papastratigakis
AKALEXANDRA KOULOUSI
ALEXANDRA KOULOUSI
CMChrysi Mandola
Chrysi Mandola
FCFoteini Chaniotaki
Foteini Chaniotaki
APAlexandra Papaioannou
Alexandra Papaioannou
Background/Objectives: 3-Hydroxy-3-methylglutaryl-CoA lyase deficiency (HMGCLD) is an extremely rare autosomal recessive metabolic disorder caused by mutations in the HMGCL gene. HMGCLD disrupts ketogenesis and β-oxidation, leading to energy failure during fasting or stress, with clinical episodes characterized by hypoglycemia, hyperammonemia, lactic acidosis, and encephalopathy. Only 211 cases have been reported worldwide, with no prior reports on anesthetic management in these patients. Methods: We report a 14.5-year-old girl with known HMGCLD who was admitted with abdominal pain and nausea following a fatty meal. Imaging confirmed acute cholecystitis. Initial conservative management failed due to persistent vomiting and inability to tolerate feeding. Deviation from the metabolic protocol led to lactic acidosis and hypoglycemia, requiring intensive care with bicarbonate, carnitine, and glucose infusion. Once optimized, she underwent emergency laparoscopic cholecystectomy under sevoflurane-based anesthesia. Propofol was avoided, given the patient’s compromised lipid metabolism. Intraoperative glucose and acid-base status were closely monitored, with balanced dextrose-based fluids. Results: The patient remained hemodynamically stable throughout and was discharged three days postoperatively. Conclusions: This case highlights the anesthetic challenges of HMGCLD, where system-level miscommunication can trigger severe metabolic decompensation. A review of the literature emphasizes fasting avoidance, continuous glucose supplementation, careful drug and fluid selection, and multidisciplinary coordination. This report provides the first anesthetic roadmap for HMGCLD, underscoring the need for individualized care and meticulous perioperative metabolic control.